TTrialPathMatch Me to Trials
← Back to trials
RecruitingClassic Follicular LymphomaFollicular Lymphoma With Unusual Cytological Features

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Eligible age

18+ yrs

Accepts

All genders

Locations

40 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

Sponsor: National Cancer Institute (NCI)

You may qualify if…

  • ✓ Participants must have a histologically confirmed diagnosis of classic follicular lymphoma (cFL). cFL was previously categorized as grade 1-3A per World Health Organization (WHO)-HAEM4R, but grading of classic follicular lymphoma (FL) is no longer mandatory.
  • ✓ NOTE: Participants with follicular lymphoma with uncommon features (uFL) are eligible, including FL with diffuse growth pattern (dFL). Diagnosis is as per local pathology. Lymphoma fluorescence in situ hybridization (FISH) is not required. Molecular testing is not required.
  • ✓ Participants must not have follicular lymphoma with "blastoid" or "large centrocyte" cytological features, or follicular large B-cell lymphoma (FLBL) (previously categorized as follicular lymphoma grade 3B)
  • ✓ Participants must have low-tumor burden follicular lymphoma defined as:
  • ✓ Nodal or extra-nodal tumor mass with diameter less than 7 cm in its greater diameter
  • ✓ Involvement of no more than 3 nodal or extra nodal sites with diameter greater than 3 cm.
  • ✓ Absence of B symptoms which may include unexplained fever, drenching sweats, unintentional weight loss (more than 10% of body weight)
  • ✓ No symptomatic splenomegaly

Where it's recruiting

Alabama

Birmingham

Arizona

Phoenix · Tucson

Arkansas

Fayetteville · Little Rock · Rogers · Springdale

California

Beverly Hills · Duarte · Irvine · Lancaster …

Colorado

Aurora · Fort Collins · Greeley · Loveland

Delaware

Newark

District of Columbia

Washington D.C.

Florida

Aventura · Coral Gables · Coral Springs · Deerfield Beach …

Georgia

Atlanta · Augusta

Idaho

Boise · Caldwell · Coeur d'Alene · Nampa …

Illinois

Bloomington · Canton · Carthage · Chicago …

Indiana

Crown Point · Dyer · Hobart · Indianapolis …

Source: ClinicalTrials.gov · NCT06337318 · last updated 2026-11-18